1 Inserm Unit 1179, Team 3: Technologies and Innovative Therapies Applied to Neuromuscular diseases, UVSQ, CIC 805, Physiology-Functional Testing Ward, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France; Nantes Université, Movement - Interactions - Performance, MIP, EA 4334, F-44000 Nantes, France. Electronic address: [email protected].
2 Inserm Unit 1179, Team 3: Technologies and Innovative Therapies Applied to Neuromuscular diseases, UVSQ, CIC 805, Physiology-Functional Testing Ward, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France; CIAMS, Univ. Paris-Sud, Université Paris-Saclay, 91405, Orsay, Cedex, France; CIAMS, Université d'Orléans, 45067, Orléans, France.
3 Inserm Unit 1179, Team 3: Technologies and Innovative Therapies Applied to Neuromuscular diseases, UVSQ, CIC 805, Physiology-Functional Testing Ward, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France.
4 Laboratory of Human Motricity, Sport, Education and Health (EA 6312), University of Nice Sophia Antipolis, France.